Cardiac Energy Metabolic Alterations in Pressure Overload–Induced Left and Right Heart Failure (2013 Grover Conference Series)-Reference-Cited by-同舟云学术

Cardiac Energy Metabolic Alterations in Pressure Overload–Induced Left and Right Heart Failure (2013 Grover Conference Series)

Published:2015-03 Issue:1 Volume:5 Page:15-28
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Sankaralingam Sowndramalingam¹,Lopaschuk Gary D.¹

Affiliation:

1. Department of PediatricsMazankowski Alberta Heart InstituteUniversity of AlbertaEdmontonCanada

Funder

Canadian Institutes of Health Research

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1086/679608

Reference129 articles.

1. Heart failure;McMurray JJ;Lancet,2005

2. Heart disease and stroke statistics—2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee;Rosamond W;Circulation,2008

3. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America;Hunt SA;Circulation,2001

4. Novel experimental model of pressure overload hypertrophy in rats;Molina EJ;J Surg Res,2009

5. Left ventricular dysfunction with pulmonary hypertension: part 1: epidemiology, pathophysiology, and definitions;Georgiopoulou VV;Circ Heart Fail,2013

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF);Biomedicine & Pharmacotherapy;2024-02

2. Retained Metabolic Flexibility of the Failing Human Heart;Circulation;2023-07-11

3. Review on the protective mechanism of astragaloside IV against cardiovascular diseases;Frontiers in Pharmacology;2023-05-11

4. Disease- and sex-specific differences in patients with heart valve disease: a proteome study;Life Science Alliance;2023-01-10

5. Metabolomics of diabetes and cardiovascular disease;Metabolomics;2023